The management of invasive bladder cancer is rapidly evolving, with an assortment of new drugs and ongoing drug trials.
Four experts will discuss current management issues Tuesday morning during a Complex Cases session titled Bladder Cancer. Arthur Sagalowsky, MD, will moderate the 20-minute session, which begins at 9:10 a.m. in Ballroom East of the Boston Convention and Exhibition Center.
“All of the topics the panel are going to cover will update practicing urologists on important advances in the evaluation and systemic management of patients with invasive bladder cancer,” said Dr. Sagalowsky, professor in Urology and Surgery at the University of Texas Southwestern Medical Center. “We’ve chosen to focus more on advances in medical therapy, rather than on surgical procedures and related issues, to help urologists remain current with the new approaches to systemic oncologic therapy, which holds the promise of major improvements in outcomes for our patients.”
The panel will discuss invasive bladder cancer cases that require differing degrees of initial metastatic evaluation, and consideration of distinct and unique types of neoadjuvant chemotherapy. The cases also involve different histological subtypes of bladder cancer.
“Importantly, for one of the cases we will examine the use of immune checkpoint inhibition,” Dr. Sagalowsky said. “The American Society of Clinical Oncology recently named Immunotherapy 2.0 as the ‘advance of the year’ in cancer management. The field of immunotherapy can be dizzying for the array of trials and drugs, but keeping up with this rapidly moving area of therapy is crucial for urologists to remain central and relevant in the management of these cases, and to continue providing the best possible care for patients.”
Bladder cancer was among the first malignancies to be treated with any type of immunotherapy — initially with bacillus Calmette-Guérin. Then in May 2016 the U.S. Food and Drug Administration approved the immune checkpoint inhibitor atezolizumab for the treatment of urothelial carcinoma. Other checkpoint inhibitors are currently under investigation for early stage and advanced forms of disease.
Dr. Sagalowsky will be joined on the panel by Igor Frank, MD, professor of Urology at the Mayo Clinic; Kris E. Gaston, MD, of the Levine Cancer Institute; and Jay B. Shah, MD, associate professor of Urology at Stanford University Medical Center.